Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa PD-L1 peptide vaccination in high-risk smoldering multiple myeloma
2018-003990-93Phase 2Completed
- Sponsor
- Department of Hematology, Herlev and Gentofte University Hospital
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-L1 long1 peptide vaccine in smoldering multiple myeloma (SMM), sponsored by Department of Hematology, Herlev and Gentofte University Hospital. Primary endpoint: Overall response rate. Started Oct 2018; status: completed.
02
Drugs
PD-L1 long1 peptide vaccine
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2018-003990-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003990-93.